Double immune attack shows promise for stubborn hodgkin lymphoma
NCT ID NCT04134325
First seen Apr 18, 2026 · Last updated May 21, 2026 · Updated 2 times
Summary
This study tests whether giving a PD-1 inhibitor drug after CAR-T cell therapy can help control Hodgkin lymphoma that has come back or not responded to other treatments. Ten adults with this type of lymphoma will receive the combination to see if it improves response rates. The goal is to harness the immune system more effectively against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.